Skip to main content
Equibles
MLTX logo

MLTX · MoonLake Immunotherapeutics · Metrics

Track MLTX — free

Use MLTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.32 +0.57 (+5.85%) At close · Oct 20
Rebalance outlook locked
Market Cap
$829.79M
Shares
85.11M
Volume · Oct 20 1.24M Avg daily vol (3M) 1.51M

MLTX metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.32
Market cap
$829.79M

Price action

20 metrics
Price change (1W)
-8.7%
Price change (30D)
-22.3%
Price change (3M)
-48.8%
Price change (6M)
-45.5%
Price change (YTD)
-26.0%
Price change (1Y)
+6.9%
Trailing year
Price change (5Y)
-1.7%
52-week high
$22.16
52-week low
$9.16
Change from 52-week high
-56.0%
Change from 52-week low
+6.4%
Annualized volatility
71.7%
Annualized volatility (3M)
49.6%
Beta
1.5
RSI (14D)
25.4
Price vs SMA 50
-27.2%
Price vs SMA 200
-41.2%
Avg volume (3M)
1.50M
Relative volume
0.6
Average dollar volume
$20.90M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
85.11M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.9
reciprocal yield 52.7%
FCF yield
-27.7%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-32.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-02-23

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$268.33M
Net income (TTM)
−$263.05M
Trailing 12 months
Diluted EPS (TTM)
$-3.85
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.90
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.82
Operating cash flow per diluted share (TTM)
$-3.25
Free cash flow per diluted share (TTM)
$-3.25
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$3.23
Stock compensation per diluted share (TTM)
$0.33
Book value per share
$-1.68

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+16.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-61.4%
Return on assets
-45.8%
Debt / equity
0.2
Current ratio
12.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$225.18M
Quick ratio
12.6
Interest coverage
-26.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$378.39M
Latest balance sheet
Cash & equivalents
$477.90M
Total assets
$573.95M
Total debt
$99.51M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$225.18M
Capital expenditures (TTM)
$0
R&D (TTM)
$221.38M
SG&A (TTM)
—
Stock compensation (TTM)
$23.20M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
175
13F filer change QoQ
+26
Institutional ownership
88.4%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
44.8%
Private-fund adviser ownership
36.2%
Active holders' share change QoQ
+18.3%
Holder tenure
8.0
Price vs estimated holder cost
+44.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.6%

Short interest

3 metrics
Short interest
9.5%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$22,000
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1821586 CUSIP 61559X104 13F (30d) 11 filings 11 filers Visit website Investor relations